JP2012512157A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512157A5
JP2012512157A5 JP2011540796A JP2011540796A JP2012512157A5 JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5 JP 2011540796 A JP2011540796 A JP 2011540796A JP 2011540796 A JP2011540796 A JP 2011540796A JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5
Authority
JP
Japan
Prior art keywords
cancer
medicament
class
selective hdac
enzastaurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011540796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/066925 external-priority patent/WO2010074936A2/en
Publication of JP2012512157A publication Critical patent/JP2012512157A/ja
Publication of JP2012512157A5 publication Critical patent/JP2012512157A5/ja
Withdrawn legal-status Critical Current

Links

JP2011540796A 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン Withdrawn JP2012512157A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
US61/122,451 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2012512157A JP2012512157A (ja) 2012-05-31
JP2012512157A5 true JP2012512157A5 (https=) 2012-08-23

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540796A Withdrawn JP2012512157A (ja) 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン

Country Status (11)

Country Link
US (1) US20110288032A1 (https=)
EP (1) EP2376081A2 (https=)
JP (1) JP2012512157A (https=)
KR (1) KR20110084533A (https=)
CN (1) CN102245184A (https=)
AU (1) AU2009330492A1 (https=)
BR (1) BRPI0922367A2 (https=)
CA (1) CA2746085A1 (https=)
EA (1) EA201170821A1 (https=)
MX (1) MX2011006433A (https=)
WO (1) WO2010074936A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CA2862320A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
JP6215235B2 (ja) * 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Similar Documents

Publication Publication Date Title
JP2012512157A5 (https=)
Mitchell Gastrointestinal toxicity of chemotherapeutic agents
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
NZ599464A (en) Combination therapies using hdac inhibitors
EA201300323A1 (ru) Материалы и способы улучшения функции желудочно-кишечного тракта
EP3738587A3 (en) Dosage form for insertion into the mouth
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
EA201100153A1 (ru) Никотинсодержащие мягкие желатиновые пастилки
EA201000855A1 (ru) Способ и средства для достижения бронхиальной релаксации
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
CU20110170A7 (es) Combinaciones farmacéuticas que comprenden rdea119/bay 869766 para el tratamiento de cánceres específicos
CY1117568T1 (el) Χρηση μιας συνθεσης η οποια περιλαμβανει φορμοτερολη και διπροπιονικη βεκλομεθαζονη για την αγωγη μιας εξαρσης ασθματος
EA201170821A1 (ru) Энзастаурин для лечения рака
ATE543492T1 (de) Behandlung von lungenkrebs
MX2010004350A (es) Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
TNSN08506A1 (en) Substituted carboxamides